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Summary objective To describe the quality of outpatient paediatric malaria case-management approximately 4–
6 months after artemether–lumefantrine (AL) replaced sulfadoxine–pyrimethamine (SP) as the
nationally recommended first-line therapy in Kenya.
methods Cross-sectional survey at all government facilities in four Kenyan districts. Main outcome
measures were health facility and health worker readiness to implement AL policy; quality of antima-
larial prescribing, counselling and drug dispensing in comparison with national guidelines; and factors
influencing AL prescribing for treatment of uncomplicated malaria in under-fives.
results We evaluated 193 facilities, 227 health workers and 1533 sick-child consultations. Health
facility and health worker readiness was variable: 89% of facilities stocked AL, 55% of health workers
had access to guidelines, 46% received in-service training on AL and only 1% of facilities had AL wall
charts. Of 940 children who needed AL treatment, AL was prescribed for 26%, amodiaquine for 39%,
SP for 4%, various other antimalarials for 8% and 23% of children left the facility without any
antimalarial prescribed. When AL was prescribed, 92% of children were prescribed correct weight-
specific dose. AL dispensing and counselling tasks were variably performed. Higher health worker’s
cadre, in-service training including AL use, positive malaria test, main complaint of fever and high
temperature were associated with better prescribing.
conclusions Changes in clinical practices at the point of care might take longer than anticipated.
Delivery of successful interventions and their scaling up to increase coverage are important during this
process; however, this should be accompanied by rigorous research evaluations, corrective actions on
existing interventions and testing cost-effectiveness of novel interventions capable of improving and
maintaining health worker performance and health systems to deliver artemisinin-based combination
therapy in Africa.
keywords malaria, change of treatment, sulfadoxine–pyremethamine, artemether–lumefantrine, health
facility evaluation, Kenya
Introduction
Artemisinin-based combination therapies (ACTs) are a
major breakthrough in the clinical management of malaria.
By 2006, 39 countries in Africa had revised their national
drug policies to incorporate ACTs into malaria case-
management guidelines (Olumese 2006). However, the
implementation of effective case-management using ACTs
faces a number of challenges, notably complex ordering
and financing procedures, unfamiliarity with the drugs
among prescribers and their introduction into weak health
systems with suboptimal drug management and clinical
practices (Rowe et al. 2000, 2001, 2003; Font et al. 2001;
Nshakira et al. 2002; Armstrong Schellenberg et al. 2004;
Eriksen et al. 2007). Therefore, despite their promise, new
ACT drugs may not reach patients who need them and if
*Re-use of this article is permitted in accordance with the Creative
Commons Deed, Attribution 2.5, which does not permit com-
mercial exploitation.
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they do, the challenge remains to ensure adequate clinical
practices. There are very few studies that have examined
the operational use of ACTs following national policy
change (Zurovac et al. 2005a, 2007).
In this paper we report on the quality of outpatient
paediatric malaria case-management in Kenyan health
facilities, approximately 4–6 months after artemether–
lumefantrine (AL) was introduced to replace
sulfadoxine–pyrimethamine (SP) as the nationally recom-
mended first-line therapy for uncomplicated malaria.
Methods
AL implementation activities in Kenya
The process surrounding the decision to abandon SP in
favour of AL, and the main characteristics of the imple-
mentation process are presented in detail elsewhere (Amin
et al. 2007). In summary, the key activities of the imple-
mentation process, important to effectively manage chil-
dren with AL, comprised: (1) revision of national malaria
case-management guidelines; (2) provision of three-day,
theoretical, cascade, in-service training for health workers;
(3) AL supply to the facilities; and (4) the distribution of
job aids (guidelines and wall charts).
Study design and data collection
Between 12 October and 19 December 2006, we studied
outpatient malaria management using a cross-sectional,
cluster sample survey at all government health facilities in
four Kenyan districts (Kwale, Bondo, Kisii ⁄Gucha and
Makueni). A cluster was defined as all outpatient encoun-
ters between a health worker and patients on a single
working day during the survey period. One survey day was
randomly allocated to each facility and all patients
presenting to outpatient departments of the surveyed
facilities were recruited on the survey day. By the time of
the surveys all districts had received at least initial supplies
of AL and an in-service training programme for health
workers had been completed. In this paper we describe
case-management practices in children below 5 years of
age, while data on patients 5 years and above will be
presented elsewhere.
Data were collected by six teams at health facilities,
each composed of two nurses, using three methods. First,
all caretakers of sick children were interviewed when they
exited the health facility. Prior to the interviews, they
provided written informed consent to participate in the
study. Interviewers collected information about the child’s
age, history of fever, main complaints, prior use of
antimalarial drugs and if the visit was an initial or follow-
up consultation. Information was collected from patient-
held records about diagnostic procedures requested and
results reported, medications prescribed, and if the patient
was treated as an outpatient or referred for hospitaliza-
tion. These records are the main communication link
between clinicians, laboratories and pharmacies within
Kenyan facilities. Furthermore, caretakers were also
interviewed about counselling and drug dispensing prac-
tices undertaken during the facility visit. During the exit
interview, all children had weight and axillary temperature
measured by study nurses. Second, at the end of the day
interviews were conducted with health workers who had
previously attended sick children to collect information on
their demographics, pre-service training, working experi-
ence, access to national guidelines, in-service training,
exposure to supervision and knowledge about antimalarial
treatment policy. If more than one health worker saw
children at a facility, all were interviewed. Finally, a health
facility assessment was performed to record the avail-
ability of supplies related to malaria case-management with
an emphasis on stocks of antimalarial drugs, availability
of malaria diagnostics and malaria treatment wall charts.
Definitions
Our definitions reflected diagnosis, treatment, drug dis-
pensing and counselling recommendations from the new
National Guideline for Diagnosis, Treatment and Pre-
vention of Malaria for Health Workers in Kenya (Ministry
of Health (MoH) 2006a)2 . According to this guideline and
in line with Integrated Management of Childhood Illnesses
(IMCI) recommendations (Ministry of Health (MoH)
2000)3 , any child below 5 years of age with fever or history
of fever in the absence of signs of severe malaria is
presumed to have uncomplicated malaria in high malaria
risk areas. For clinical management purposes all study
districts are classified as a high risk area and the presence
of history of fever despite the presence of other signs
presents sufficient criterion to suspect and treat for
malaria (Ministry of Health (MoH) 2000, 2006a).
Although these recommendations do not consider parasi-
tological diagnosis, the guideline in this patient group
ambiguously states that parasitological diagnosis is not
pre-requisite for the treatment (Ministry of Health (MoH)
2006a). To address this ambiguity we defined a case of
uncomplicated malaria as a child who presented to a
health facility for an initial visit with a history of fever
during the present illness or axillary temperature
‡37.5 C, and who was treated as an outpatient in the
absence of a negative malaria test.
For uncomplicated malaria, we defined recommended
treatment as prescription of AL for children ‡5 kg and
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quinine for children <5 kg. The correctness of AL dosage
prescriptions was assessed based on weight-specific
categories and classified into three categories:
(1) recommended (six tablets for a child weighing
5–14 kg and 12 tablets for a child weighing 15–24 kg),
(2) overdosed and (3) underdosed prescriptions. The
quality of AL dispensing and counselling for patients
included performance of the following tasks: weighing of
patients, administration of the first dose at the health
facility, observation of swallowing of the first dose,
explanation on how to take AL at home, advising on
taking AL after a meal and provision of advice on what
to do in case of vomiting.
Data entry and statistical analysis
Data were double entered by independent data entry
clerks and verified using Access 2000 (Microsoft Inc.,
Redmond, WA, USA). The analysis was performed using
stata, version 8 (StataCorp, College Station, TX, USA).
The precision of proportions [95% confidence interval
(CI)] was estimated accounting for the cluster sampling
design using ‘health facility-day’ as the primary sampling
unit.
We applied a stepwise approach in descriptive analysis
of the quality of malaria case-management. Our primary
analysis focused on the antimalarial treatment practices for
children with uncomplicated malaria who needed to have
AL prescribed. To assess overall performance of the new
policy and to assess health workers’ adherence to the new
treatment policy, analysis was undertaken at all health
facilities and then limited to facilities with AL in stock on
the survey day. Then, the quality of AL dosage prescrip-
tions, drug dispensing and counselling received by children
with uncomplicated malaria at facilities with available AL
who had this drug prescribed was analysed. For compar-
ison purposes this analysis was also undertaken on children
meeting the same criteria but who had amodiaquine
prescribed.
Finally, to explore factors influencing AL prescriptions,
we analysed a series of health facility, health worker and
patient level factors applying logistic regression modelling
with the STATA xtgee procedure using an exchangeable
working correlation matrix (Horton & Lipsitz 1999). This
procedure uses generalized estimating equations to account
for the correlated nature of the data. The analysis was
restricted to children with an antimalarial drug prescribed
at facilities with AL in stock. In the univariate analysis we
estimated odds ratios (OR), P-values and 95% CIs for the
association between health workers’ decision to prescribe
AL and the following factors: health workers’ pre-service
training; in-service training on the use of AL; access to
national malaria guidelines; availability of amodiaquine;
presence of AL wall charts; supervision including AL
prescription; presence of positive malaria test; the child’s
temperature; and the child’s main complaints. Factors with
P-value <0.15 were entered into multivariate model.
Hypothesis testing and CI estimation were done with an
alpha level of 0.05.
Ethical approval
Ethical approval for this study was provided by the
KEMRI national ethical review committee (reference
number 892) and by the Boston University Institutional
Review Board (2004-127B and H-24055).
Results
Description of the sample
We evaluated outpatient malaria management at 193
health facilities where 228 health workers performed
outpatient consultations on the day of the survey. Of 228
health workers, one (0.4%) left the facility before an
interview could be performed and could not be found over
the next 2 days. There were 1533 consultations evaluated
for children <5 years of age and no caretaker of the sick
children refused participation in the study. Of 1533 sick-
child consultations, 983 met our definition of uncompli-
cated malaria. The other 550 consultations were follow-up
visits, had neither a history of fever nor temperature
‡37.5 C, or had negative blood slides reported at the
health facility. A further seven children were excluded from
the analysis because they did not have a weight measured.
Of the remaining 976 children with uncomplicated
malaria, 940 (96.3%) weighed ‡5 kg.
Health facility and health worker readiness to deliver AL
Of 193 health facilities assessed, 172 (89%) had received
AL with a median number of 48 days (interquartile range:
37–54) since the first receipt. On the day of the survey, any
tablets of AL were available in 169 (88%) facilities;
however, the availability of weight-specific AL blister
packages ranged from 59% for 24 tablet packs to 87% for
12 tablet packs (Table 1). All 193 facilities stocked
amodiaquine, nearly all had SP (95%) and quinine tablets
were available in 80% of facilities. The facilities were well
equipped with weighing scales (99%) and thermometers
(80%); however, only 36% of facilities had the capacity to
perform a parasitological diagnosis of malaria, more
commonly using microscopy (29%) than rapid diagnostic
tests (10%). Parasitological capacity to diagnose malaria
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was available in all hospitals, 77% of health centres and
20% of dispensaries. Only one facility had displayed AL
case-management wall charts.
Of 227 health workers interviewed, 105 (46%) had
received in-service training on AL use, most commonly
through the cascade malaria case-management training
(103 ⁄105; 98%) (Table 2). Fifty-five per cent of health
workers had access to a copy of the new national malaria
case-management guideline recommending use of AL and
29% had IMCI guidelines that did not contain AL
recommendations. Only 17 (8%) health workers reported
a supervisory visit that included discussions on appropriate
use of AL. Although only half of the health workers
interviewed had received in-service training, 70%
responded correctly that AL is the recommended first-line
treatment for uncomplicated malaria in patients weighing
>5 kg, whereas only 30% provided the correct response for
children weighing <5 kg (quinine).
Antimalarial treatments for children with uncomplicated
malaria
Table 2 shows antimalarial treatments for children who
needed AL prescribed at all facilities studied and separately
at facilities where AL was in stock on the day of the survey.
At all health facilities AL was prescribed for only 26% of
children, amodiaquine for 39%, SP for 4%, various other
antimalarials for 8% of children and, importantly, 23% of
children left the facility without any antimalarial drug
prescribed. Of 36 children <5 kg who were excluded from
Table 2 and needed oral quinine according to national
Table 1 Characteristics of the health facilities and health workers
in four districts in Kenya
Characteristics
All districts,
n (%)
Health facility characteristics (n = 193)
Health facility type
Hospital 14 (7.3)
Health centre 35 (18.1)
Dispensary 144 (74.6)
Equipment and services at health facility
Weighing scale 191 (99.0)
Thermometer 155 (80.3)
Functional microscopy 55 (28.5)
Malaria rapid diagnostic test 19 (9.8)
Any malaria diagnostic service
(rapid diagnostic test or microscopy)
70 (36.3)
Wall charts
Artemether–lumefantrine case-management chart 1 (0.5)
IMCI chart 5 (2.6)
Availability of artemether–lumefantrine on the
survey day
Any tablets of artemether–lumefantrine 169 (87.6)
Artemether–lumefantrine six tablets pack 163 (84.5)
Artemether–lumefantrine 12 tablets pack 168 (87.1)
Artemether–lumefantrine 18 tablets pack 160 (82.9)
Artemether–lumefantrine 24 tablets pack 114 (59.1)
Availability of other antimalarial drugs on
the survey day
Amodiaquine (any formulation) 193 (100)
Sulfadoxine–pyrimethamine (any formulation) 183 (94.8)
Quinine (tablets) 154 (79.8)
Health worker characteristics (n = 227)
Pre-service training
Doctor 2 (0.9)
Clinical officer 45 (19.8)
Nurse 150 (66.1)
Cadre without formal clinical training* 30 (13.2)
In-service training
Malaria case-management training on
artemether–lumefantrine
103 (45.4)
IMCI training 51 (22.5)
IMCI training including artemether–lumefantrine 6 (2.6)
Any training including
artemether–lumefantrine
(malaria-specific or IMCI)
105 (46.3)
Access to guidelines
National malaria case-management guideline 126 (55.5)
IMCI guideline 65 (28.6)
Any supervisory visit including appropriate
use of artemether–lumefantrine
17 (7.5)
Knowledge of new treatment policy
Treatment above 5 kg
(artemether–lumefantrine)
158 (69.6)
Treatment below 5 kg (quinine) 69 (30.4)
IMCI, Integrated Management of Childhood Illnesses.
*This category includes 15 nursing aides, 11 community health
workers, two public health technicians and two clerks.
Table 2 Antimalarial treatments for children weighing ‡5 kg with
uncomplicated malaria in Kenya
All facilities (n = 940)
Facilities with AL in
stock (n = 866)
n (%) 95% CI n (%) 95% CI
AL 248 (26.4) 19.9–32.9 243 (28.1) 21.2–34.9
AQ 363 (38.6) 32.5–44.8 318 (36.7) 30.3–43.1
SP 41 (4.4) 1.5–7.2 28 (3.2) 1.3–5.2
AQ + SP 26 (2.8) 1.4–5.4 26 (3.0) 0.2–5.8
Quinine 14 (1.5) 0.5–2.4 13 (1.5) 0.5–2.5
Other
antimalarial
treatments*
31 (3.3) 1.7–4.9 29 (3.4) 1.6–5.1
No
antimalarial
prescribed
217 (23.1) 18.9–27.3 209 (24.1) 19.7–28.6
AL, artemether–lumefantrine; AQ, amodiaquine; SP, sulfadoxine–
pyrimethamine; QN, quinine.
*Other antimalarial treatments include dehydroartemisinin,
AQ + QN, SP + QN, AL + QN and AQ + SP + QN.
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guidelines, 17 had amodiaquine prescribed, four various
other antimalarials and 15 were not provided an antima-
larial; none of these children had oral quinine prescribed.
Restricting the analysis to facilities where AL was in stock
on the day of the survey, no significant changes in
adherence to AL recommendations were observed: 28% of
children had AL prescribed, amodiaquine continued to be
the health workers’ preference and the pattern of other
antimalarial prescriptions was the same as was observed in
the descriptions of all facilities (Table 2).
Quality of AL dosage prescriptions, drug dispensing and
counselling
When AL was prescribed, health workers prescribed it in
correct weight-specific dosage for 92% of children, while
overdosed and underdosed AL prescriptions were rare
(2% and 6%, respectively; Table 3). Indeed, correct
weight-specific prescriptions of AL were far more com-
mon than those of amodiaquine, which was correctly
prescribed for only 15% of children (Table 3). Two
hundred and forty-one children who received AL at the
health facility were advised and counselled with varying
degrees of adherence to guideline recommendations.
Yet, these tasks were performed more commonly when
AL was prescribed than for children who were prescribed
amodiaquine (Table 4).
Predictors influencing AL prescriptions
We examined 13 factors that might have influenced
prescribing of AL in 657 children with uncomplicated
malaria who were prescribed an antimalarial at facilities
where AL was in stock on the day of the survey. After
univariate analysis the following factors did not meet
entrance criteria (P-value >0.15) for the multivariate
model: health worker’s supervision including AL prescrip-
tion (OR = 1.90; 95% CI: 0.65–5.61), main complaints of
cough (OR = 0.93; 95% CI: 0.73–1.18), diarrhoea
(OR = 1.20; 95% CI: 0.92–1.58) and ear problem
(OR = 0.74; 95% CI: 0.32–1.70). In the multivariate
model the following factors were significantly associated
(P-value <0.05) with higher likelihood of AL prescription:
health worker’s pre-service training, in-service training
including AL use, presence of a positive malaria test, main
complaint of fever and temperature ‡37.5 C (Table 5). In
the same model, health worker’s access to national
guidelines and main complaints of skin problem were not
Table 3 Correctness of artemether–lume-
fantrine and amodiaquine dosage prescrip-
tions
Recommended,
n (%)
Overdose,
n (%)
Underdose,
n (%)
Dosage not
specified
Artemether–lumefantrine
All children ‡5 kg (n = 248) 228 (91.9) 5 (2.0) 14 (5.7) 1 (0.4)
5–14 kg (n = 220) 212 (96.4) 5 (2.3) 2 (0.9) 1 (0.5)
15–24 kg (n = 28) 16 (57.1) 0 12 (42.9) 0
Amodiaquine
All children ‡ 5 kg (n = 363) 53 (14.6) 132 (36.4) 174 (47.9) 4 (1.1)
5–6 kg (n = 46) 6 (13.0) 18 (39.1) 21 (45.7) 1 (2.2)
7–9 kg (n = 144) 24 (16.7) 54 (37.5) 66 (45.8) 0
10–14 kg (n = 135) 19 (14.1) 48 (35.6) 65 (48.2) 3 (2.2)
15–18 kg (n = 32) 4 (12.5) 11 (34.4) 17 (53.1) 0
19–37 kg (n = 6) 0 1 (16.7) 5 (83.3) 0
Table 4 Dispensing and counselling prac-
tices for children who had artemether–
lumefantrine and amodiaquine dispensed
Artemether–lumefan-
trine (n = 241) Amodiaquine (n = 357)
n (%) 95% CI n (%) 95% CI
Weight measured 167 (69.3) 58.8–79.8 133 (37.3) 26.6–47.9
First dose given at the facility 92 (38.2) 24.8–51.6 17 (4.8) 2.0–7.5
Swallowing of first dose observed 83 (34.4) 21.0–47.9 13 (3.6) 1.1–6.2
Dosage explained 234 (97.1) 95.0–99.2 346 (96.9) 95.0–98.8
Advice provided to take
drug after a meal
91 (37.8) 28.0–47.5 n.a. n.a.
Advice provided what to
do in case of vomiting
19 (7.9) 3.8–11.9 19 (5.3) 2.0–8.7
n.a., not applicable.
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significantly associated with measured outcome. The
factors such as availability of amodiaquine and the
presence of AL wall charts could not be analysed because
they were either universally present or absent in the data
set.
Discussion
Regular supply of adequate quantities of AL is crucial to
any effective implementation plan. The results of our
survey suggest that the majority (88%) of health facilities
stocked AL; however, this remains far from perfect as one
in ten facilities did not have any AL. The short interval
between rolling out the AL drug supply and timing of our
survey does not allow for any meaningful evaluation of the
stability of the AL supply chain and estimates of stock-out
durations. Nevertheless the drug supply challenges not only
relate to the adequate supply of AL but also to the removal
of ineffective drugs from the supply system. Our results
show that amodiaquine was in stock in all facilities, a
finding which is at variance with the stated national AL
implementation plan recommending phasing-out of this
drug (Ministry of Health (MoH) 2006b)4 .
The Kenyan MoH set a target of 60% of front-line
health workers to be trained before the delivery of AL to
the health facilities (Amin et al. 2007). Across the four
districts included in the present study, approximately
2 months after the delivery of AL to facilities, only 46% of
health workers had received any specific training in the
new guidelines. Notably 2 years after the delivery of AL to
facilities in Zambia only 41% of health workers had
received any training in the use of AL (Zurovac et al.
2007). The initial training exercise in Kenya cost approx-
imately 1.5 million USD (Amin et al. 2007). To expand
coverage of in-service training quickly and efficiently,
cheaper, simplified and shortened on-job training options
should be considered using, for example, trained clinical
supervisors at the district level or communication of case-
management messages through job aids.
By the time of our survey the distribution of job aids to
support training and implementation of new policy had
achieved mixed results. While 55% of health workers had
access to a copy of the new guidelines either distributed
during the training programmes or independently, only one
health facility had newly produced AL case-management
wall charts. Although the availability of wall charts
showed mixed results on malaria treatment practices in the
past (Zurovac & Rowe 2006), it is worrying that, by the
time of the study, this intervention, which was already
developed at the national level, did not reach health
workers at the periphery of the health system. As they are a
simple, inexpensive intervention to improve prescribing
Table 5 Factors influencing health work-
er’s decision to prescribe artemether–lume-
fantrine: results of multivariate analysis
Factor
No. of
consultations
No. (%) with
artemether–lumefantrine
prescribed OR (95% CI) P-value
Health worker’s pre-service training
Clinical officer 112 71 (63.4) 5.10 (1.10–23.68) 0.038
Nurse 404 162 (40.1) 3.65 (0.97–13.66) 0.055
No formal
training
141 10 (7.1) 1.0 (Ref.)
Health worker received in-service training on artemether–lumefantrine
Yes 266 155 (58.3) 2.58 (1.20–5.52) 0.014
No 391 88 (22.5) 1.0 (Ref.)
Health worker has access to national malaria guideline
Yes 407 182 (44.7) 1.58 (0.74–3.37) 0.234
No 250 61 (24.4) 1.0 (Ref.)
Positive malaria test
Yes 49 42 (85.7) 10.59 (2.62–42.73) 0.001
No 608 201 (33.1) 1.0 (Ref.)
Fever main complaint
Yes 601 231 (38.4) 2.14 (1.17–3.91) 0.014
No 56 12 (21.4) 1.0 (Ref.)
Temperature ‡37.5 C
Yes 225 108 (48.0) 1.37 (1.03–1.82) 0.030
No 432 135 (31.3) 1.0 (Ref.)
Skin problem main complaint
Yes 68 22 (32.4) 0.75 (0.49–1.16) 0.203
No 589 221 (37.5) 1.0 (Ref.)
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practices, the use of wall charts should be optimally
implemented.
Despite some successes in delivery of AL to facilities and
provision of in-service training, many children who should
have received AL either were not treated or received
suboptimal therapy with an alternative drug. Health
workers had discontinued using SP (4%) but had an
increased tendency to prescribe amodiaquine (39%) rather
than AL (26%). While this practice is understandable at
facilities without AL in stock, it is worrying that the same
findings were revealed in facilities where AL was available.
Furthermore, almost one in four children who should have
received an antimalarial drug left the facility without any
antimalarial. Similar findings (23%) were reported under
AL treatment policy in Zambia (Zurovac et al. 2007).
Compared to the results of the previous surveys undertaken
under SP policy in Kenya (9%) (Zurovac et al. 2004) and
chloroquine policy in Benin (6%) (Rowe et al. 2003), it
appears that these practices are on the rise under the new
AL policy. Further case-management interventions will
need to pay particular attention to ensure that all febrile
children receive an effective antimalarial treatment as
recommended by national and international guidelines
(Gove 1997; World Health Organisation (WHO) 2006).
More positively, when health workers decided to
prescribe AL the quality of correct dosage prescription,
drug dispensing and counselling was generally better for
the new, more complex to use AL, than for more the
familiar, less complex to use amodiaquine (Tables 3 and
4). These findings are encouraging in the light of previous
findings under monotherapies that commonly reported
incorrect dosing (Font et al. 2001; Nshakira et al. 2002;
Zurovac et al. 2005b), poorer drug dispensing and coun-
selling (Rowe et al. 2001; Armstrong Schellenberg et al.
2004; Zurovac et al. 2005b) and it was expected that the
challenges under AL policy would be even greater (Zuro-
vac & Rowe 2006). We are glad to report that our earlier
concerns seem to be unfounded, most likely due to
deployment of weight-specific blister packaging of AL
providing clear dosing instructions not only to patients but
also to health workers.
Our factor analysis provides some explanations that help
understand deficiencies in prescribing antimalarial drugs.
AL was more commonly prescribed by higher clinical
cadres such as clinical officers than by nurses and health
workers without formal clinical training. The opposite was
observed during the era of SP policy in Kenya (Zurovac
et al. 2004) and chloroquine policy in Benin (Rowe et al.
2003). One explanation is that there was some uncertainty
among the Kenyan legislation revisions to allow prescrib-
ing of AL for lower cadres of health workers such as nurses
(Amin et al. 2007). Furthermore, our findings reveal that
not only nurses but also health workers without formal
clinical training commonly perform consultations at the
periphery of formal health system, although they are not
officially allowed to do so. This problem was not antici-
pated during the AL implementation process and should be
urgently addressed. Common programmatic interventions
such as in-service training of health workers, distribution
of guidelines and supervision including AL were variably
associated with better prescribing practices in facilities
where AL was in stock (Table 5). This has been an area of
conflicting results in other settings; not all routine
in-service initiatives to improve clinical management
practices have had positive effects on treatment practices
(Ross-Degnan et al. 1997; Rowe et al. 2000, 2001, 2003;
World Health Organisation (WHO) 2001;5 Naimoli et al.
2006; Osterholt et al. 2006; Zurovac & Rowe 2006). In
the present study perhaps the most important observation
was that health workers who had been exposed to in-
service training were three times more likely to prescribe
AL to febrile children compared with those who had not
received any training. As such this intervention worked but
reached only 46% of health workers.
A series of patient factors deserve special attention.
Children with a positive malaria test were 11 times more
likely to have AL prescribed compared with children who
were not tested. One possible explanation is that given the
emphasis during training on the ‘rational use’ of AL
through the use of diagnostics in adults, this message may
have influenced the stated policy of presumptive treatment
with AL for children. Our analysis further demonstrated
that children presenting with a main complaint of fever or
increased temperature were more likely to have AL
prescribed, similar to reports from elsewhere in Africa
(Rowe et al. 2003; Zurovac et al. 2004; Osterholt et al.
2006). This suggests that health workers might consider
fever less significant in children, meriting less effective
treatment, if temperature is not increased or if caretakers
do not voluntarily report fever. Such practices may fail to
result in the appropriate treatment of malaria. Health
workers should be instructed to treat all fevers equally
since it is well known that diagnostic reliance on only
obvious fevers is likely to miss malaria diagnoses in young
children (Gove 1997; World Health Organisation (WHO)
2006)6 .
Finally, a series of subtle qualitative factors could not be
examined in this study. For example, AL is an expensive
drug on the private market and, although it is provided for
free by the government, the subjective perceptions of health
workers of AL as an expensive drug may influence
prescribing. Furthermore, some of the case-management
messages, such as those on the inefficacy of amodiaquine,
use of malaria tests and presumptive diagnosis among
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others, may not have not have reached health workers at
the periphery. In-depth investigation of these potential
hypotheses using qualitative research methods is
underway.
The Kenyan experience reported here, after only a few
months of AL policy implementation, suggests that the
changes in clinical practices at the point of care might take
longer than anticipated. The constant, uninterrupted sup-
ply of drugs to facilities will ultimately determine how well
the new policy is effective in reaching those in need of these
medicines in the formal health sector. This obvious pre-
requisite, however needs to be augmented by programme
activities that withdraw ineffective medicines, train health
workers in new guidelines, improve quality of supervision
and constantly monitor ambiguities and buried messages in
guidelines that effect correct prescription. Finally, it is also
time to evaluate new, potentially cheaper and more
effective approaches (e.g. provision of on-job training,
delivery of non-monetary incentives, application of case-
management reminders using text-messaging to health
workers mobile phones) that might change clinical practice
among health workers at the periphery of the health
system.
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